Summary
There is a significant number of patients still not at their LDL-cholesterol goal. The talk focuses on the benefit of providing access to different available non-statin lipid-lowering agents for appropriate ASCVD patients together with a discussion of their impact on vascular inflammation, endothelial function, and clinical outcome.
Our mission: To reduce the burden of cardiovascular disease.